Targeting of angiopoietin 2‑small interfering RNA plasmid/chitosan magnetic nanoparticles in a mouse model of malignant melanoma in vivo

Shan,Xiu‑Ying; Xu,Ting‑Ting; Liu,Zhao‑Liang; Hu,Xue‑Feng; Zhang,Yan‑Ding; Guo,Shu‑Zhong; Wang,Biao

doi:10.3892/ol.2017.6443

Targeting of angiopoietin 2‑small interfering RNA plasmid/chitosan magnetic nanoparticles in a mouse model of malignant melanoma in vivo

Authors:
- Xiu‑Ying Shan
- Ting‑Ting Xu
- Zhao‑Liang Liu
- Xue‑Feng Hu
- Yan‑Ding Zhang
- Shu‑Zhong Guo
- Biao Wang
View Affiliations

Affiliations: Department of Plastic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, College of Life Sciences, Fujian Normal University, Fuzhou, Fujian 350108, P.R. China
Published online on: June 21, 2017 https://doi.org/10.3892/ol.2017.6443
Pages: 2320-2324
Copyright: © Shan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to observe the in vivo targeting characteristic of angiopoietin 2-small interfering RNA (Ang2‑siRNA) plasmid/chitosan magnetic nanoparticles in an established nude mouse model of malignant melanoma (MM) under an external magnetic field. The nude mouse MM model was first established, then divided into 3 groups, including the control group, the non‑targeting group and the target group, the control group was given normal saline and the non‑targeting and targeting groups were administrated particles through the tail vein; the non‑targeting group was not under external magnetic field and the control group and the targeting group were under external magnetic field for 60 min. The mice were then sacrificed and the tumor tissues were stained with hematoxylin and eosin and Prussian blue in order to verify the particle distributions in the tumor tissues. The control group exhibited negative Prussian blue staining in the tumor tissues, the non‑targeting group demonstrated weakly positive Prussian blue staining in tumor tissues and the targeting group revealed strongly positive Prussian blue staining in tumor tissues. Ang2‑siRNA plasmid vector/chitosan magnetic nanoparticles directly moved towards tumor tissues under the action of external magnetic field, thus it demonstrated good targeting characteristic.

View Figures

View References

1	Dong X and Mumper RJ: Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress. Nanomedicine (Lond). 5:597–615. 2010. View Article : Google Scholar : PubMed/NCBI
2	de Bono JS and Ashworth A: Translating cancer research into targeted therapeutics. Nature. 467:543–549. 2010. View Article : Google Scholar : PubMed/NCBI
3	Widder KJ, Senyel AE and Scarpelli GD: Magnetic microshperes: A model system for site specific drug delivery in vivo. Proc Soc Exp Biol Med. 158:pp. 141–146. 1978; View Article : Google Scholar : PubMed/NCBI
4	Yang X, Chen Y, Yuan R, Chen G, Blanco E, Gao J and Shuai X: Folate-encoded and Fe3O4-loaded polymeric micelles for dual targeting of cancer cells. Polymer. 49:3477–3485. 2008. View Article : Google Scholar
5	Kim KY: Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine. 3:103–110. 2007. View Article : Google Scholar : PubMed/NCBI
6	Gao J and Xu B: Applications of nanomaterials inside cells. Nano Today. 4:37–51. 2009. View Article : Google Scholar
7	Berry CC, Wells S, Charles S and Curtis AS: Dextran and albumin derivatised iron oxide nanoparticles: Influence on fibroblasts in vitro. Biomaterials. 24:4551–4557. 2003. View Article : Google Scholar : PubMed/NCBI
8	Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G and Cohen S: Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A. 65:489–497. 2003. View Article : Google Scholar : PubMed/NCBI
9	Liu ZL, You CL, Wang B, Lin JH, Hu XF, Shan XY, Wang MS, Zheng HB and Zhang YD: Construction of Ang2-siRNA chitosan magnetic nanoparticles and the effect on Ang2 gene expression in human malignant melanoma cells. Oncol Lett. 11:3992–3998. 2016.PubMed/NCBI
10	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
11	Venza M, Visalli M, Beninati C, De Gaetano GV, Teti D and Venza I: Cellular mechanisms of oxidative stress and action in melanoma. Oxid Med Cell Longev. 2015:4817822015. View Article : Google Scholar : PubMed/NCBI
12	Häfeli UO: Magnetically modulated therapeutic systems. Int J Pharm. 277:19–24. 2004. View Article : Google Scholar : PubMed/NCBI
13	Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, Kang HW and Jon S: Thermally cross-linked superparamagnetic iron oxide nanoparticles: Synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc. 129:12739–12745. 2007. View Article : Google Scholar : PubMed/NCBI
14	Unger E, Porter T, Lindner J and Grayburn P: Cardiovascular drug delivery with ultrasound and microbubbles. Adv Drug Deliv Rev. 72:110–126. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sehrig F Zeinali, Majidi S, Nikzamir N, Nikzamir N, Nikzamir M and Akbarzadeh A: Magnetic nanoparticles as potential candidates for biomedical and biological applications. Artif Cells Nanomed Biotechnol. 44:918–927. 2016.PubMed/NCBI
16	Ishii T, Okahata Y and Sato T: Mechanism of cell transfection with plasmid/chitosan complexes. Biochim Biophys Acta. 1514:51–64. 2001. View Article : Google Scholar : PubMed/NCBI
17	Yu B, Tai HC, Xue W, Lee LJ and Lee RJ: Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 27:286–298. 2010. View Article : Google Scholar : PubMed/NCBI
18	Torchilin VP: Passive and active drug targeting: Drug delivery to tumors as an example. Handb Exp Pharmacol. 1–53. 2010.PubMed/NCBI
19	Wang HH, Wang YX, Leung KC, Au DW, Xuan S, Chak CP, Lee SK, Sheng H, Zhang G, Qin L, et al: Durable mesenchymal stem cell labelling by using polyhedral superparamagnetic iron oxide nanoparticles. Chemistry. 15:12417–12425. 2009. View Article : Google Scholar : PubMed/NCBI
20	Hsieh WJ, Liang CJ, Chieh JJ, Wang SH, Lai IR, Chen JH, Chang FH, Tseng WK, Yang SY, Wu CC and Chen YL: In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int J Nanomedicine. 7:2833–2842. 2012.PubMed/NCBI
21	Zhou X, Zhang M, Yung B, Li H, Zhou C, Lee LJ and Lee RJ: Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int J Nanomedicine. 7:5465–5474. 2012.PubMed/NCBI
22	Maruyama K: Intracelluar targeting delivery of liposomal drugs to solid tumors based on EPR effect. Adv Drug Deliv Rev. 63:161–169. 2011. View Article : Google Scholar : PubMed/NCBI
23	Payne SJ and Jones L: Influence of the tumor microenvironment on angiogenesis. Future Oncol. 7:395–408. 2011. View Article : Google Scholar : PubMed/NCBI
24	Danquah MK, Zhang XA and Mahtao RI: Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 63:623–639. 2011. View Article : Google Scholar : PubMed/NCBI
25	Neuberger T, Schöpf B, Hofmann H, Hofmann M and Rechenberg BV: Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater. 293:483–496. 2005. View Article : Google Scholar
26	Lammers T, Kiessling F, Hennink WE and Storm G: Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release. 161:175–187. 2012. View Article : Google Scholar : PubMed/NCBI
27	Yi GQ, Gu B and Chen LK: The safety and efficacy of magnetic nano-iron hyperthermia therapy on rat brain glioma. Tumour Biol. 35:2445–2449. 2014. View Article : Google Scholar : PubMed/NCBI